The pharmaceutical world is observing a remarkable shift in blood sugar therapy with the introduction of GLP-1 skin applications. These devices offer a seemingly more convenient alternative to shots of GLP-1 receptor agonists, minimizing the requirement of daily needle pokes. The approach adminis